Mandate

Vinge advises Capio in connection with acquisition of Scanloc

September 01, 2016

Scanloc conducts operations relating to specialist care within eye disorders at clinics situated in Gothenburg and Kungsbacka. The company’s customers primarily consist of the Västra Götaland and Halland County Councils. Scanloc has 35 employees and will be part of Capio Medocular. Closing is scheduled for 30 September and is conditional upon the customary closing conditions from the salient public authorities.

Vinge’s team consisted of responsible partner Anders Strid together with, among others, Frida Bäckergren (project manager), Frida Mattsson (employment), Victor Ericsson (tax) and Gabriella Fossum (public procurement).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025